Successful use of fenfluramine as an add‐on treatment for Dravet syndrome

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Epilepsia

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1528-1167.2012.03495.xPMID 22554283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What is an open label trial?

  2014cited by this paper
• Clinical course of young patients with Dravet syndrome after vagal nerve stimulation.

  2011cited by this paper
• The pharmacologic treatment of Dravet syndrome

  2011cited by this paper
• The core Dravet syndrome phenotype

  2011cited by this paper
• The genetics of Dravet syndrome

  2011influential reference
• Overall management of patients with Dravet syndrome

  2011cited by this paper
• Dravet syndrome: The long‐term outcome

  2011cited by this paper
• Nonpharmacologic treatments of Dravet syndrome: Focus on the ketogenic diet

  2011cited by this paper
• Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later

  2011cited by this paper
• Protocadherin 19 mutations in girls with infantile-onset epilepsy

  2010cited by this paper
• Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.

  2009cited by this paper
• A long‐term follow‐up study of Dravet syndrome up to adulthood

  2009influential reference
• Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes

  2009cited by this paper
• SCN1A duplications and deletions detected in Dravet syndrome: Implications for molecular diagnosis

  2009influential reference
• Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy.

  2009cited by this paper
• Dravet syndrome and deep brain stimulation: Seizure control after 10 years of treatment

  2009cited by this paper
• Stiripentol open study in Japanese patients with Dravet syndrome

  2009cited by this paper
• Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals

  2008cited by this paper
• Coping With a Child With Dravet Syndrome: Insights From Families

  2008cited by this paper
• An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy

  2007cited by this paper
• Epilepsy in Children in Navarre, Spain: Epileptic Seizure Types and Epileptic Syndromes

  2007influential reference
• The spectrum of SCN1A-related infantile epileptic encephalopathies.

  2007cited by this paper
• Microdeletions involving the SCN1A gene may be common in SCN1A‐mutation‐negative SMEI patients

  2006cited by this paper
• Severe myoclonic epilepsy of infancy (Dravet syndrome): Recognition and diagnosis in adults

  2006cited by this paper
• Topiramate in the Treatment of Highly Refractory Patients with Dravet Syndrome

  2006cited by this paper
• The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant.

  2005cited by this paper
• Severe myoclonic epilepsy in infancy: Dravet syndrome.

  2005cited by this paper
• Epileptic Syndromes in Infancy, Childhood and Adolescence

  2004cited by this paper
• Severe Myoclonic Epilepsy in Infancy: Toward an Optimal Treatment

  2004cited by this paper
• Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial.

  2002cited by this paper
• [Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome)].

  2002cited by this paper
• Fenfluramine as a potential antiepileptic drug.

  2002cited by this paper
• Efficacité et tolérance à long terme du stiripentol dans le traitement de l’épilepsie myoclonique sévère du nourrisson (syndrome de Dravet)

  2002cited by this paper
• De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.

  2001cited by this paper
• Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels.

  2001cited by this paper
• Severe myoclonic epilepsy in infants--a review based on the Tokyo Women's Medical University series of 84 cases.

  2001cited by this paper
• Fenfluramine-Phentermine (Fen-Phen) and Seizures: Evidence for an Association.

  2000cited by this paper
• Topiramate in the treatment of severe myoclonic epilepsy in infancy.

  2000cited by this paper
• Fenfluramine Blocks Low‐Mg2+‐Induced Epileptiform Activity in Rat Entorhinal Cortex

  2000cited by this paper
• Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial

  2000cited by this paper
• Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.

  2000cited by this paper
• Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.

  1997cited by this paper
• Add-On Therapy of Fenfluramine in Intractable Self-Induced Epilepsy

  1996cited by this paper
• Long‐Term Course of Childhood Epilepsy with Intractable Grand Mal Seizures

  1992cited by this paper
• Early diagnosis of severe myoclonic epilepsy in infancy.

  1992cited by this paper
• Epidemiology of Severe Myoclonic Epilepsy of Infancy

  1990cited by this paper
• Syncopal attacks compulsively self-induced by Valsalva's maneuver associated with typical absence seizures. A case report.

  1988cited by this paper
• Dopamine agonist treatment of self-induced pattern-sensitive epilepsy. A case report.

  1988cited by this paper
• Compulsive respiratory stereotypies in children with autistic features: Polygraphic recording and treatment with fenfluramine

  1987cited by this paper
• Treatment of self-induced photosensitive epilepsy with fenfluramine.

  1985cited by this paper
• Proposal for Revised Clinical and ~lectro~nce~halo ~ra~hic Classification of Epileptic Seizures From the Commission on Classification and Terminology of the International League Against Epilepsy*

  1981cited by this paper
• Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic Seizures

  1981cited by this paper
• Les epilepsies graves de l'enfant

  1978cited by this paper

• Dravet syndrome therapeutics: where are we, what works, and what’s next?

  2025cites this paper
• Developmental and Epileptic Encephalopathies: Progress in Understanding and Clinical Implications

  2025cites this paper
• Nonseizure Outcomes in Dravet Syndrome: Potential Impact of Pharmacotherapy

  2025cites this paper
• Fenfluramine's Broader Potential: A Second Notable Electroencephalogram Response in Developmental Epileptic Encephalopathy With Spike‐Wave Activation in Sleep

  2025cites this paper
• Diazepine Agonists of the 5‑HT2C Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352)

  2025cites this paper
• A Postmarketing Pharmacovigilance Study of Fenfluramine: Adverse Event Data Mining and Analysis Based on the US Food and Drug Administration Public Data Open Project (openFDA).

  2025cites this paper
• Machine learning enables high-throughput, low-replicate screening for novel anti-seizure targets and compounds using combined movement and calcium fluorescence in larval zebrafish.

  2025cites this paper
• From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications.

  2025cites this paper
• Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database

  2025cites this paper
• Zebrafish models of developmental epileptic encephalopathy accurately reflect clinical electrographic biomarkers

  2025cites this paper
• Enhancing the action of serotonin by three different mechanisms prevents spontaneous seizure‐induced mortality in Dravet mice

  2024cites this paper
• Behavioral and neurotransmitter changes on antiepileptic drugs treatment in the zebrafish pentylenetetrazol-induced seizure model.

  2024cites this paper
• Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes

  2024cites this paper
• Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome

  2024cites this paper
• Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term

  2024cites this paper
• Resolution of Fenfluramine-associated pulmonary arterial hypertension in Lennox-Gastaut syndrome: A case report and literature review

  2024cites this paper
• Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight

  2024cites this paper
• Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies.

  2024cites this paper
• Developmental and epileptic encephalopathies

  2024cites this paper
• Unraveling the genetic basis of epilepsy: Recent advances and implications for diagnosis and treatment.

  2024cites this paper
• Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies

  2024cites this paper
• Carvedilol increases seizure resistance in a mouse model of SCN8A-derived epilepsy

  2024cites this paper
• Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden

  2024cites this paper
• Selective Serotonin Reuptake Inhibitors and 5-HT2 Receptor Agonists Have Distinct, Sleep-state Dependent Effects on Postictal Breathing in Amygdala Kindled Mice

  2023cites this paper
•  Drug-Resistant Epilepsy; An Overview on Management and Treatment

  2023cites this paper
• Clinical and Genetic Features of Dravet Syndrome: A Prime Example of the Role of Precision Medicine in Genetic Epilepsy

  2023cites this paper
• Utilizing an acute hyperthermia-induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome

  2023cites this paper
• Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding

  2023cites this paper
• Neurostimulation for Generalized Epilepsy: Should Therapy be Syndrome-specific?

  2023cites this paper
• Revisiting the concept of drug‐resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force

  2023cites this paper
• Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies

  2023cites this paper
• Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial

  2023cites this paper
• SCN1A as a therapeutic target for Dravet syndrome

  2023cites this paper
• Sigma-1 receptor and seizures

  2023cites this paper
• Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis

  2023cites this paper
• Comorbidities and predictors of health‐related quality of life in Dravet syndrome: A 10‐year, prospective follow‐up study

  2023cites this paper
• Fenfluramine treatment for Dravet syndrome: Caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom.

  2023cites this paper
• Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine

  2022cites this paper
• Dravet syndrome: Advances in etiology, clinical presentation, and treatment.

  2022cites this paper
• Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

  2022cites this paper
• SCN1B Genetic Variants: A Review of the Spectrum of Clinical Phenotypes and a Report of Early Myoclonic Encephalopathy

  2022cites this paper
• Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.

  2022cites this paper
• Fenfluramine for the Treatment of Dravet Syndrome and Lennox Gastaut Syndrome: A Review

  2022cites this paper
• Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis

  2022cites this paper
• Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum.

  2022cites this paper
• Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy

  2022cites this paper
• Was können die neuen anfallssupprimierenden Medikamente?

  2022cites this paper
• Comparative effectiveness of fenfluramine versus cannabidiol in their licensed indications for the treatment of seizures in Dravet Syndrome: a systematic review and network meta-analysis

  2022cites this paper
• Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective.

  2022cites this paper
• Antidepressant Drugs for Seizures and Epilepsy: Where do we Stand?

  2022cites this paper
• Impact of Antiseizure Medications on Appetite and Weight in Children

  2022cites this paper
• Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials

  2022cites this paper
• A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication

  2022cites this paper
• New and emerging pharmacologic treatments for developmental and epileptic encephalopathies

  2022cites this paper
• Therapeutic drug monitoring of fenfluramine in clinical practice: Pharmacokinetic variability and impact of concomitant antiseizure medications

  2022cites this paper
• A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome

  2021cites this paper
• Cardiac adverse effects of antiseizure medications

  2021cites this paper
• Anticonvulsant Agents: Cannabidiol and Fenfluramine

  2021cites this paper
• A review of fenfluramine for the treatment of Dravet syndrome patients

  2021cites this paper
• Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe

  2021cites this paper
• Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome.

  2021cites this paper
• Long-term Efficacy of Perampanel in a Child with Dravet Syndrome

  2021cites this paper
• Lieven Lagae

  2021cites this paper
• Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies.

  2021cites this paper
• Monogenic Epilepsies

  2021cites this paper
• Rational Small Molecule Treatment for Genetic Epilepsies

  2021cites this paper
• X-linked serotonin 2C receptor is associated with a non-canonical pathway for sudden unexpected death in epilepsy

  2021cites this paper
• Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany

  2021cites this paper
• Zebrafish as a Model of Genetic Epilepsy and Its Co-occurring Neurobehavioral and Neuropsychiatric Features

  2021cites this paper
• Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.

  2021cites this paper
• The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies

  2021cites this paper
• Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome

  2021cites this paper
• Antiepileptogenesis and disease modification: Progress, challenges, and the path forward—Report of the Preclinical Working Group of the 2018 NINDS‐sponsored antiepileptogenesis and disease modification workshop

  2021cites this paper
• Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know.

  2021cites this paper
• Voltage Gated Sodium Channel Genes in Epilepsy: Mutations, Functional Studies, and Treatment Dimensions

  2021cites this paper
• Serotonergic therapy in epilepsy

  2021cites this paper
• Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome

  2021cites this paper
• Cannabinoids and Neuropsychiatric Disorders

  2021cites this paper
• Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis.

  2021cites this paper
• The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results

  2021cites this paper
• Fenfluramine as antiseizure medication for epilepsy

  2021cites this paper
• Dravet syndrome—toward an optimal and disease-specific treatment

  2021cites this paper
• Therapeutic advances in Dravet syndrome: a targeted literature review

  2020cites this paper
• Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential.

  2020cites this paper
• Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers.

  2020cites this paper
• Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression

  2020cites this paper
• Changing Landscape of Dravet Syndrome Management: An Overview

  2020cites this paper
• New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndrome

  2020cites this paper
• Epilepsy: key experimental therapeutics in early clinical development

  2020cites this paper
• Advances in the Treatment of Drug-Resistant Pediatric Epilepsy

  2020cites this paper
• Fenfluramine hydrochloride for the treatment of Dravet syndrome

  2020influential citation
• You Can Teach an Old Drug New Tricks

  2020cites this paper
• Seizing the moment: Zebrafish epilepsy models.

  2020cites this paper
• Seizures in Children

  2020cites this paper
• Post-ictal generalized EEG suppression and seizure-induced mortality are reduced by enhancing dorsal raphe serotonergic neurotransmission

  2020cites this paper
• Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study

  2020cites this paper
• Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome

  2020cites this paper
• Investigating Developmental and Epileptic Encephalopathy Using Drosophila melanogaster

  2020cites this paper
• Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real‐world study

  2020cites this paper
• Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study

  2020cites this paper